Provided by Tiger Trade Technology Pte. Ltd.

Ardelyx

5.50
-0.0500-0.90%
Volume:3.41M
Turnover:18.48M
Market Cap:1.35B
PE:-21.52
High:5.54
Open:5.50
Low:5.30
Close:5.55
52wk High:8.40
52wk Low:3.21
Shares:245.25M
Float Shares:232.53M
Volume Ratio:1.35
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2556
EPS(LYR):-0.2556
ROE:-36.21%
ROA:-5.46%
PB:8.08
PE(LYR):-21.52

Loading ...

Ardelyx Raised to Overweight From Neutral by Piper Sandler

Dow Jones
·
Jan 09

Piper Sandler Upgrades Ardelyx to Overweight From Neutral

MT Newswires Live
·
Jan 09

Ardelyx price target raised to $14 from $11 at Citi

TIPRANKS
·
Jan 09

Ardelyx: Strengthening Commercial Trajectory, Expanded IP Protection to 2041, and Pipeline Upside Support Raised $17 Buy Target

TIPRANKS
·
Jan 09

BUZZ-Ardelyx jumps as Piper Sandler highlights strong Ibsrela uptake

Reuters
·
Jan 09

Ardelyx Is Maintained at Buy by BTIG

Dow Jones
·
Jan 09

U.S. RESEARCH ROUNDUP-Ardelyx, RPM International, Trubridge

Reuters
·
Jan 09

Ardelyx Inc : Btig Raises Target Price to $17 From $14

THOMSON REUTERS
·
Jan 09

Ardelyx upgraded to Overweight from Neutral at Piper Sandler

TIPRANKS
·
Jan 09

Ardelyx price target raised to $19 from $16 at Raymond James

TIPRANKS
·
Jan 09

Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX) and Allogene Therapeutics (ALLO)

TIPRANKS
·
Jan 09

Assessing Ardelyx (ARDX) Valuation After Mixed Long Term Shareholder Returns

Simply Wall St.
·
Jan 08

Ardelyx files procedural regulatory disclosure update notice

TIPRANKS
·
Jan 08

Ardelyx Provides 2026 Revenue Guidance for Ibsrela, Xphozah

MT Newswires Live
·
Jan 08

BRIEF-Ardelyx Reports Preliminary 2025 Revenue And Provides 2026 Strategic Outlook

Reuters
·
Jan 08

Ardelyx sees FY26 revenue IBSRELA between $410M-$430M

TIPRANKS
·
Jan 08

Ardelyx reports preliminary FY25 product revenue $378M

TIPRANKS
·
Jan 08

Ardelyx expects IBSRELA revenue to reach $1B in 2029

TIPRANKS
·
Jan 08

Ardelyx Projects 2026 IBSRELA Revenue of Up to $430 Million

Reuters
·
Jan 08

Ardelyx Receives Notice of Allowance for Patent Covering IBSRELA and XPHOZAH Formulations, Extending Protection to 2041

Reuters
·
Jan 08